• AAPL 189.82
  • TSLA 177.46
  • AMZN 184.7
  • MSFT 420.21
  • INTC 31.85
  • EURUSD 1.088
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. BR /
  3. SEQUA.BR

Sequana Medical NV (SEQUA BR) stock market data APIs

€1.71 0.05(3%) as of May 17, 2024

Sequana Medical NV Financial Data Overview

1.66
1.71
-
1.75
1.655
1.35-4.85
50 204 K
30 244 K
712 K
0
0.837
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'SEQUA',
Type: 'Common Stock',
Name: 'Sequana Medical NV',
Exchange: 'BR',
CurrencyCode: 'EUR',
CurrencyName: 'Euro',
CurrencySymbol: '€',
CountryName: 'Belgium',
CountryISO: 'BE',
OpenFigi: NULL,
ISIN: 'BE0974340722',
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Medical Devices',
}

Sequana Medical NV Fundamental Data is available in our Financial Data APIs

  • Net Revenue 712 K
  • EBITDA -29 136 836
  • Earnings Per Share -1.32
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Sequana Medical NV Earnings via APIs

  • Latest Release 2024-05-23
  • EPS/Forecast -0.29

Get Sequana Medical NV End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Sequana Medical NV latest news via APIs

Sequana Medical announces 2021 Full Year Results and 2022 Outlook

alfapump®in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months vs. published literaturePatient enrolment and implants compl...
  • BRUSSELS STOCK EXCHANGE:SEQUA
  • EARNINGS RELEASES AND OPERATING RESULTS
  • SEQUANA MEDICAL

Sequana Medical announces 2021 Full Year Results and 2022 Outlook

Sequana Medical alfapump®in liver disease Positive results from second interim analysis of POSEIDON pivotal study; encouraging survival data at 12 months vs. published literature Patient enrolment ...
  • DSR
  • HEART FAILURE
  • LIVER CIRRHOSIS
  • LIVER DISEASE
  • MALIGNANT ASCITES
  • MEDICAL DEVICE REGULATION
  • PRE-CLINICAL DEVELOPMENT
  • PRIMARY ENDPOINT
  • SAHARA DESERT
  • SEQUANA
  • SEQUANA MEDICAL
Do you have any questions?
support@eodhistoricaldata.com